Welcome to our dedicated page for Kazia Therapeutics American Depositary Shares news (Ticker: KZIA), a resource for investors and traders seeking the latest updates and insights on Kazia Therapeutics American Depositary Shares stock.
Kazia Therapeutics Limited (NASDAQ: KZIA) is an innovative biotechnology company focused on oncology, based in Sydney, Australia. The company is dedicated to developing cutting-edge anti-cancer drugs, with a robust pipeline aimed at addressing various forms of cancer.
The lead program for Kazia is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway. Paxalisib is primarily developed for treating glioblastoma multiforme, a highly aggressive brain cancer. Licensed from Genentech in late 2016, paxalisib has been the subject of numerous clinical trials. A Phase II study reported promising clinical activity, and the drug is currently undergoing pivotal trials, with additional studies targeting brain metastases and other central nervous system (CNS) cancers.
Besides paxalisib, Kazia is advancing EVT801, a small-molecule VEGFR3 inhibitor, licensed from Evotec SE in April 2021. EVT801 has shown preclinical efficacy across a range of tumor types and synergy with immuno-oncology agents. It's currently in Phase I clinical trials for advanced solid tumors.
Another notable drug in Kazia’s pipeline is Cantrixil (TRXE-002-1), under development for ovarian cancer and in Phase I clinical trials in Australia and the United States.
Kazia’s commitment to innovation and collaboration is evident through strategic partnerships and licensing agreements. For example, they recently signed a non-binding Letter of Intent with a biotechnology company to develop and commercialize paxalisib outside oncology, targeting epilepsy related to focal cortical dysplasia type 2 and tuberous sclerosis complex.
Financially, Kazia remains focused on securing funding to sustain its research and development endeavors. The company recently announced a direct offering expected to generate approximately $2 million.
Additionally, Kazia's forward-looking strategy includes addressing market listing requirements and ensuring compliance with Nasdaq’s Minimum Bid Price Requirement.
For more information, visit www.kaziatherapeutics.com or follow them on Twitter @KaziaTx.
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) announced that CEO Dr. James Garner will present at two investor conferences. The first is the HC Wainwright Global Investment Conference in Miami, FL, from May 23-26, 2022, where he will discuss upcoming news from Kazia's clinical programs. The second is the LD Micro Invitational XII in Westlake Village, CA, from June 7-9, 2022, focusing on the company's licensing strategy and progress on paxalisib, its lead program targeting glioblastoma. Institutional investors can register for one-on-one meetings.
Kazia Therapeutics Limited (NASDAQ: KZIA) acknowledges 'DIPG Awareness Day' on May 17, 2022, highlighting the urgent need for increased awareness and research funding for childhood brain cancer, especially diffuse intrinsic pontine glioma (DIPG). This type of cancer has no FDA-approved treatment and a median survival of 9-11 months. Kazia's investigational drug, paxalisib, is under a phase II study for DIPG, with data expected in 2023. New preclinical data will be presented at the ISPNO Conference in June 2022, emphasizing the potential of paxalisib in offering hope to affected families.
Kazia Therapeutics Limited (NASDAQ: KZIA) announced the final data from its phase II study of paxalisib for newly diagnosed glioblastoma will be presented at the ASCO Annual Meeting from June 3-7, 2022, in Chicago, IL. The poster titled 'Paxalisib in patients with newly diagnosed glioblastoma' will take place on June 5, 2022. Abstracts will be released on May 26, 2022. Kazia specializes in oncology and is advancing paxalisib, recognized for its efficacy against brain tumors, alongside other therapies like EVT801.
Kazia Therapeutics Limited (NASDAQ: KZIA) announced promising preclinical data on paxalisib, showcased in three abstracts at the AACR Annual Meeting. The findings highlight paxalisib's efficacy in treating childhood brain cancers, particularly atypical teratoid/rhabdoid tumors (AT/RT) and diffuse intrinsic pontine glioma (DIPG), both of which lack FDA-approved therapies. Notably, paxalisib demonstrated survival benefits when combined with other cancer treatments. The ongoing phase II clinical trial in DIPG furthers its potential. Kazia aims to explore wider applications for paxalisib in pediatric brain cancers.
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) announced two poster presentations at the AACR Annual Meeting in New Orleans, detailing the phase I study of EVT801, a VEGFR3 inhibitor targeting advanced cancer. The study aims to assess safety, tolerability, and pharmacokinetics while employing innovative biomarker strategies to identify effective patient profiles. EVT801 is a promising candidate licensed from Evotec and commenced patient recruitment in November 2021, with initial data expected in the second half of 2022.
Kazia Therapeutics announces progress in its pivotal GBM AGILE study for lead asset paxalisib, with data expected in CY23. Recent US C-suite appointments indicate a focus on commercialization. The second asset, EVT801, is in human trials, with the first patient enrolled in France. The company's valuation has increased to US$294m or US$22.28 per basic ADR, driven by NPV roll-forward, despite lower cash and higher R&D costs. Net cash stood at US$11.0m as of December 31, 2021, indicating a runway into H123.
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) announced upcoming presentations at two key events. Scheduled for April 8-13, 2022, at the American Association of Cancer Research Annual Scientific Meeting in New Orleans, four abstracts related to their drug pipeline will be presented. This includes updates on EVT801 and paxalisib, both pivotal in treating advanced cancers. Additionally, CEO Dr. James Garner will discuss corporate progress at the 2022 Virtual Growth Conference from March 28-30, 2022. These presentations highlight Kazia's commitment to oncology research and drug development.
Kazia Therapeutics Limited (NASDAQ: KZIA) announces the initiation of a phase II clinical study of paxalisib combined with metformin and a ketogenic diet for treating glioblastoma at Weill Cornell Medicine. The trial will recruit 30-60 patients over two years, aiming to enhance treatment efficacy through a low-insulin state. Dr. Howard Fine will lead the trial, which is expected to yield significant data read-outs throughout 2022, including insights on progression-free survival. Kazia continues its commitment to advancing glioblastoma treatment, with multiple ongoing studies.
Kazia Therapeutics Limited (NASDAQ: KZIA) will present at the BIO CEO Conference in New York from February 14-17, 2022. CEO Dr. James Garner will deliver an update on the company's clinical-stage oncology programs, including paxalisib, a treatment for glioblastoma, and EVT801, a small-molecule inhibitor targeting various tumor types. The conference, hosted by the Biotechnology Innovation Organization, connects biotech companies with investors and analysts. Attendees can register via the conference website.
Kazia Therapeutics Limited (NASDAQ: KZIA) announced its CEO, Dr. James Garner, will speak at the virtual Edison Group 'Open House' Event from January 25-27, 2022. Kazia is among 33 healthcare companies participating in this event, showcasing innovations in pharmaceuticals and technology. The presentation will occur on January 26, with on-demand access available from 8 AM GMT. Interested investors can register for free here.
FAQ
What is the current stock price of Kazia Therapeutics American Depositary Shares (KZIA)?
What is the market cap of Kazia Therapeutics American Depositary Shares (KZIA)?
What is Kazia Therapeutics’ primary focus?
What is paxalisib?
What stage are paxalisib’s clinical trials in?
What other drugs are in Kazia’s pipeline?
How is Kazia financing its projects?
What recent partnerships has Kazia formed?
What are the latest clinical trial developments for EVT801?
How does Kazia ensure compliance with Nasdaq’s listing requirements?
What is the significance of Kazia’s licensing agreement with Sovargen Co., Ltd?
Where can I find more information about Kazia Therapeutics?
